Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Blood
Michael R GreenMargaret A Shipp

Abstract

Classical Hodgkin lymphoma (cHL) and mediastinal large B-cell lymphoma (MLBCL) are lymphoid malignancies with certain shared clinical, histologic, and molecular features. Primary cHLs and MLBCLs include variable numbers of malignant cells within an inflammatory infiltrate, suggesting that these tumors escape immune surveillance. Herein, we integrate high-resolution copy number data with transcriptional profiles and identify the immunoregulatory genes, PD-L1 and PD-L2, as key targets at the 9p24.1 amplification peak in HL and MLBCL cell lines. We extend these findings to laser-capture microdissected primary Hodgkin Reed-Sternberg cells and primary MLBCLs and find that programmed cell death-1 (PD-1) ligand/9p24.1 amplification is restricted to nodular sclerosing HL, the cHL subtype most closely related to MLBCL. Using quantitative immunohistochemical methods, we document the association between 9p24.1 copy number and PD-1 ligand expression in primary tumors. In cHL and MLBCL, the extended 9p24.1 amplification region also included the Janus kinase 2 (JAK2) locus. Of note, JAK2 amplification increased protein expression and activity, specifically induced PD-1 ligand transcription and enhanced sensitivity to JAK2 inhibition. Therefo...Continue Reading

References

Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Sep 30, 2003·European Journal of Immunology·Spencer C LiangArlene H Sharpe
Mar 27, 2004·Blood·Chrystelle GuiterFlavia Castellano
Oct 12, 2004·Biostatistics·Adam B OlshenMichael Wigler
Jun 28, 2005·Nucleic Acids Research·Stein AertsBart De Moor
Oct 6, 2005·Journal of Leukocyte Biology·Simone MocellinHoward A Young
Nov 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhenfeng DuanMichael V Seiden
Jan 20, 2007·Bioinformatics·E S Venkatraman, Adam B Olshen
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Junzo HamanishiShingo Fujii
Apr 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takeo NomiYoshiyuki Nakajima
Aug 3, 2007·Proceedings of the National Academy of Sciences of the United States of America·Przemyslaw JuszczynskiMargaret A Shipp
Nov 21, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Julia MenkeVicki R Kelley
Dec 14, 2007·Proceedings of the National Academy of Sciences of the United States of America·Rameen BeroukhimWilliam R Sellers
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
Mar 19, 2008·Journal of Cancer Research and Clinical Oncology·Lei GengShusen Zheng
May 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Raanan BergerArnon Nagler
Jun 13, 2008·Nature Protocols·Thomas D Schmittgen, Kenneth J Livak
Aug 30, 2008·Molecular Cancer Therapeutics·Jacqueline SayyahPeter P Sayeski
Sep 6, 2008·Nature·UNKNOWN Cancer Genome Atlas Research Network
Sep 9, 2008·Critical Reviews in Oncology/hematology·Maurizio MartelliPeter Johnson
Dec 17, 2008·Proceedings of the National Academy of Sciences of the United States of America·David G BrooksMichael B A Oldstone
Dec 17, 2008·Nature Reviews. Cancer·Ralf Küppers
Dec 18, 2008·Proceedings of the National Academy of Sciences of the United States of America·Michal MarzecMariusz A Wasik
Feb 4, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Qiang GaoJia Fan
Dec 17, 2009·The Journal of Experimental Medicine·Loise M FranciscoArlene H Sharpe
Mar 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Srdan Verstovsek
Jul 1, 2008·Current Hematologic Malignancy Reports·Michael FuchsUNKNOWN German Hodgkin Study Group

❮ Previous
Next ❯

Citations

Jul 27, 2012·Current Hematologic Malignancy Reports·Kieron DunleavyWyndham H Wilson
Aug 9, 2011·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Franziska C EberleElaine S Jaffe
Aug 2, 2011·Nature Genetics·Laura PasqualucciRiccardo Dalla-Favera
Sep 22, 2011·Nature Immunology·Lixin RuiLouis M Staudt
Mar 23, 2012·Nature Reviews. Cancer·Matthew Vanneman, Glenn Dranoff
Nov 13, 2013·Nature Reviews. Clinical Oncology·Mark RoschewskiWyndham H Wilson
Jan 25, 2012·The Journal of Experimental Medicine·Oliver WeigertDavid M Weinstock
Aug 9, 2012·Current Opinion in Oncology·Amanda Copeland, Anas Younes
May 16, 2013·Current Opinion in Hematology·Laura Pasqualucci
Sep 29, 2011·The Cancer Journal·Christopher S Hourigan, Hyam I Levitsky
Jan 25, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael R GreenMargaret A Shipp
Oct 2, 2012·The Journal of Clinical Investigation·Ralf KüppersMartin-Leo Hansmann
Dec 14, 2011·Hematology·Elaine S Jaffe, Stefania Pittaluga
Dec 12, 2012·Blood·Paul Greaves, John G Gribben
Nov 8, 2012·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Radka NedomovaMarie Jarosova
Jul 23, 2013·Seminars in Cancer Biology·Yuxuan LiuAnke van den Berg
Jun 22, 2014·Current Hematologic Malignancy Reports·Anna Dabrowska-Iwanicka, Jan A Walewski
Sep 7, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T K ChoueiriS Signoretti
Dec 3, 2014·Hematology/oncology Clinics of North America·Nishitha M Reddy, Miguel-Angel Perales
Nov 25, 2014·Nature Biotechnology·Mukesh BansalUNKNOWN NCI-DREAM Community
Jan 22, 2011·Advances in Hematology·Pier Paolo PiccalugaStefano A Pileri
Mar 1, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Catherine Diefenbach, Christian Steidl
Jan 11, 2014·Cancer Immunology Research·Bridget P KeenanTodd D Armstrong
Nov 14, 2014·Leukemia & Lymphoma·David D W Twa, Christian Steidl
Nov 20, 2015·Expert Review of Hematology·Benjamin KasendaIan Chau
Sep 24, 2015·Pharmaceuticals·Natalie S Grover, Steven I Park
May 6, 2015·Cancers·Ranjan UpadhyayJoshua D Brody
Nov 19, 2015·Expert Review of Anticancer Therapy·Jose C Villasboas, Stephen M Ansell
Sep 8, 2015·Expert Review of Hematology·Komal Dumaswala, Amitkumar Mehta
Dec 30, 2014·Expert Review of Hematology·Maurizio MartelliRobin Foà
Feb 21, 2013·Expert Opinion on Biological Therapy·Omid Hamid, Richard D Carvajal
Feb 28, 2013·Expert Opinion on Investigational Drugs·Enrico Derenzini, Anas Younes
Jun 8, 2015·Current Opinion in Hematology·Anja Mottok, Christian Steidl
Apr 13, 2012·Expert Opinion on Investigational Drugs·Brian L HarryAntonio Jimeno
Feb 24, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Miguel-Angel PeralesPhilippe Armand
Feb 7, 2016·Genes, Chromosomes & Cancer·Katrien Van RoosbroeckIwona Wlodarska
Oct 4, 2015·Biochimica Et Biophysica Acta·Yi XiaKen H Young

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.